DK3215493T3 - Syntese af copanlisib og dihydrochloridsalt deraf - Google Patents

Syntese af copanlisib og dihydrochloridsalt deraf Download PDF

Info

Publication number
DK3215493T3
DK3215493T3 DK15790150.5T DK15790150T DK3215493T3 DK 3215493 T3 DK3215493 T3 DK 3215493T3 DK 15790150 T DK15790150 T DK 15790150T DK 3215493 T3 DK3215493 T3 DK 3215493T3
Authority
DK
Denmark
Prior art keywords
copanlisib
synthesis
dihydrochloride salt
dihydrochloride
salt
Prior art date
Application number
DK15790150.5T
Other languages
English (en)
Inventor
Jan-Georg Peters
Philipp Rubenbauer
Franz-Josef Mais
Heiko Schirmer
Juergen Stiehl
Kai Lovis
Andreas Lender
Martin Seyfried
Theodor Zweifel
Maurus Marty
Günter Weingärtner
Daniel Götz
Danja Grossbach
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of DK3215493T3 publication Critical patent/DK3215493T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK15790150.5T 2014-11-07 2015-11-05 Syntese af copanlisib og dihydrochloridsalt deraf DK3215493T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192203.9A EP3018127A1 (en) 2014-11-07 2014-11-07 Synthesis of copanlisib and its dihydrochloride salt
PCT/EP2015/075789 WO2016071435A2 (en) 2014-11-07 2015-11-05 Synthesis of copanlisib and its dihydrochloride salt

Publications (1)

Publication Number Publication Date
DK3215493T3 true DK3215493T3 (da) 2019-05-06

Family

ID=51866061

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15790150.5T DK3215493T3 (da) 2014-11-07 2015-11-05 Syntese af copanlisib og dihydrochloridsalt deraf

Country Status (46)

Country Link
US (1) US10494372B2 (da)
EP (2) EP3018127A1 (da)
JP (1) JP6691115B2 (da)
KR (1) KR102566834B1 (da)
CN (1) CN107278204B (da)
AR (1) AR102570A1 (da)
AU (1) AU2015341788B2 (da)
BR (1) BR112017009470B1 (da)
CA (1) CA2966800C (da)
CL (1) CL2017001131A1 (da)
CO (1) CO2017004532A2 (da)
CR (1) CR20170184A (da)
CU (1) CU24489B1 (da)
CY (1) CY1121602T1 (da)
DK (1) DK3215493T3 (da)
DO (1) DOP2017000112A (da)
EA (1) EA035558B1 (da)
EC (1) ECSP17027755A (da)
ES (1) ES2721778T3 (da)
HR (1) HRP20190720T1 (da)
HU (1) HUE042866T2 (da)
IL (1) IL251874A0 (da)
JO (1) JO3644B1 (da)
LT (1) LT3215493T (da)
MA (1) MA40895B1 (da)
ME (1) ME03358B (da)
MX (1) MX366904B (da)
MY (1) MY189852A (da)
NI (1) NI201700054A (da)
NZ (1) NZ731287A (da)
PE (1) PE20170897A1 (da)
PH (1) PH12017500833A1 (da)
PL (1) PL3215493T3 (da)
PT (1) PT3215493T (da)
RS (1) RS58579B1 (da)
SA (1) SA517381462B1 (da)
SG (1) SG11201703702RA (da)
SI (1) SI3215493T1 (da)
SV (1) SV2017005433A (da)
TN (1) TN2017000179A1 (da)
TR (1) TR201905217T4 (da)
TW (1) TWI697495B (da)
UA (1) UA122398C2 (da)
UY (1) UY36392A (da)
WO (1) WO2016071435A2 (da)
ZA (1) ZA201703867B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CU24400B1 (es) 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
WO2016142312A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
HUE063178T2 (hu) 2017-09-08 2023-12-28 Bayer Pharma AG Kopanlizib formulációi
WO2023139125A1 (en) 2022-01-18 2023-07-27 Synthon B.V. Improved process for preparation of copanlisib
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003580A (en) 1910-08-10 1911-09-19 Remington Typewriter Co Type-writing machine.
US6221877B1 (en) * 2000-04-12 2001-04-24 Regents Of The University Of California Substituted 4-phthalimidocarboxanilides as inhibitors of purine salvage phosphoribosyltransferases
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) * 2001-04-13 2003-12-11 Kaneka Corp Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
CN100506817C (zh) * 2001-08-15 2009-07-01 纳幕尔杜邦公司 用于防治无脊椎害虫的邻-杂环取代的芳基酰胺类化合物
ATE411996T1 (de) 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CA2713388C (en) 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CU24400B1 (es) 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
US10117874B2 (en) 2013-12-03 2018-11-06 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142312A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
WO2016142313A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
BR112018015783A2 (pt) 2016-02-01 2018-12-26 Bayer Pharma AG biomarcadores de copanlisibe
WO2017134000A1 (en) 2016-02-01 2017-08-10 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors

Also Published As

Publication number Publication date
SG11201703702RA (en) 2017-06-29
CR20170184A (es) 2017-06-20
SV2017005433A (es) 2018-04-30
MY189852A (en) 2022-03-14
US10494372B2 (en) 2019-12-03
CA2966800C (en) 2023-02-21
TWI697495B (zh) 2020-07-01
BR112017009470A2 (en) 2018-01-02
DOP2017000112A (es) 2017-06-15
JP2017534631A (ja) 2017-11-24
HK1245774A1 (zh) 2018-08-31
IL251874A0 (en) 2017-06-29
CL2017001131A1 (es) 2018-01-19
JP6691115B2 (ja) 2020-04-28
MX366904B (es) 2019-07-30
WO2016071435A3 (en) 2016-06-30
KR102566834B1 (ko) 2023-08-16
PT3215493T (pt) 2019-05-21
LT3215493T (lt) 2019-04-25
UA122398C2 (uk) 2020-11-10
RS58579B1 (sr) 2019-05-31
MA40895A (fr) 2017-09-13
EP3018127A1 (en) 2016-05-11
PH12017500833A1 (en) 2017-10-18
EA201790983A1 (ru) 2017-10-31
ECSP17027755A (es) 2017-06-30
HUE042866T2 (hu) 2019-07-29
TR201905217T4 (tr) 2019-05-21
CO2017004532A2 (es) 2017-07-19
EP3215493B1 (en) 2019-01-23
US20180282337A1 (en) 2018-10-04
SA517381462B1 (ar) 2021-01-25
CN107278204B (zh) 2019-12-17
MA40895B1 (fr) 2019-07-31
EP3215493A2 (en) 2017-09-13
TN2017000179A1 (en) 2018-10-19
UY36392A (es) 2016-06-30
CN107278204A (zh) 2017-10-20
PL3215493T3 (pl) 2019-07-31
CA2966800A1 (en) 2016-05-12
JO3644B1 (ar) 2020-08-27
NI201700054A (es) 2017-07-17
ES2721778T3 (es) 2019-08-05
KR20170082563A (ko) 2017-07-14
TW201625634A (zh) 2016-07-16
WO2016071435A2 (en) 2016-05-12
CU20170061A7 (es) 2017-10-05
HRP20190720T1 (hr) 2019-06-14
EA035558B1 (ru) 2020-07-07
MX2017005893A (es) 2017-06-30
ME03358B (me) 2019-10-20
BR112017009470B1 (pt) 2022-11-01
NZ731287A (en) 2023-01-27
AR102570A1 (es) 2017-03-08
CU24489B1 (es) 2020-12-17
AU2015341788B2 (en) 2020-01-16
PE20170897A1 (es) 2017-07-12
AU2015341788A1 (en) 2017-05-18
SI3215493T1 (sl) 2019-05-31
ZA201703867B (en) 2019-07-31
CY1121602T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
IL284874A (en) Valbenazine salts and polymorphs thereof
DK3259253T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3140310T3 (da) Syntese af boronatsalte og brug deraf
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3215493T3 (da) Syntese af copanlisib og dihydrochloridsalt deraf
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3218005T3 (da) Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3099800T3 (da) Ekspression og oprensning af crm197 og beslægtede proteiner
IL272851A (en) Methods of using dipivefrin
DK3389669T3 (da) Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
ZA201703866B (en) Synthesis of copanlisib and its dihydrochloride salt
HRP20181441T1 (hr) Inhibitori sintaze aldosterona
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3418273T3 (da) Derivater af flavagliner
DK3180335T3 (da) Cytokrom-p450-inhibitorer og anvendelser deraf
DK3370756T3 (da) Kombination af canrenoat og exenatid
DK3191464T3 (da) Syntese af isoflavaner og intermediater deraf